Clonidine Liquid Formulation pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solid oral formulations of clonidine pose challenges for patients with swallowing difficulties, mental disorders, or those without access to water, leading to medication errors and compliance issues, particularly for low therapeutic index drugs like clonidine, where extemporaneous suspensions can be unsafe and result in overdoses.
Innovation Solution
A liquid pharmaceutical composition of clonidine or its pharmaceutically acceptable salts, formulated with a combination of Sodium Dihydrogen Phosphate and Disodium Phosphate as a buffer, and a preservative, maintaining a pH range of 4-7, which is stable, palatable, and offers uniform dosing without physical stability issues or medication errors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If solid oral formulations are used for clonidine, then manufacturing ease and storage stability are improved, but patient compliance deteriorates due to swallowing difficulties and lack of water access
Solution Approach 1:
The patent changes the physical state parameter of clonidine from solid to liquid formulation. This fundamental parameter change enables the medication to be administered without water and makes it suitable for patients with swallowing difficulties, while maintaining stability through specific pH control (4-7) and preservative systems.
2Ease of operation
If extemporaneous suspensions are prepared from solid formulations, then liquid administration is achieved, but medication errors and overdoses increase due to compounding errors
Solution Approach 1:
The patent applies preliminary action by pre-formulating clonidine in a stable liquid solution with controlled pH (4-7) and appropriate preservatives during manufacturing. This eliminates the need for extemporaneous compounding by healthcare workers, ensuring consistent dosing concentrations and eliminating preparation errors while maintaining liquid administration advantages.
Solution Approach 2:
The patent creates a standardized liquid formulation that replicates the therapeutic effect of solid formulations but in a safer, pre-prepared liquid form. The standardized manufacturing process ensures accurate dosing concentrations are consistently reproduced, eliminating variability inherent in manual compounding.
3Ease of operation
If suspension formulations are used, then liquid administration is provided, but physical stability deteriorates due to sedimentation and compaction
Solution Approach 1:
The patent changes the formulation type from suspension to true liquid solution. By dissolving clonidine in an aqueous vehicle with controlled pH (4-7) rather than suspending particles, the formulation eliminates sedimentation and compaction issues while maintaining liquid administration benefits. The solution remains physically stable without requiring shaking or special storage conditions.
Data Source
AI summary
The present invention relates to liquid pharmaceutical composition suitable for oral administration comprising clonidine or pharmaceutically acceptable salts thereof with at least one buffer and at least one preservative. The present invention also relates to process for preparing the said liquid pharmaceutical composition.